Success Story: Speedy EB1A Approval! Our Firm Helped a Research Assistant Professor from India Succeed in 18 Days
Client’s Testimonial:
“Working with Chen on my I-140 preparation and filing was truly an outstanding experience. The attention to detail and focused preparation on every component of the petition were exceptional. My attorney and her associates were consistently professional, responsive, and supportive throughout the entire process. Truly appreciate the dedication and efficiency, which made a stressful process feel smooth and manageable. I would always recommend NAmILG for such excellent support!”
On June 14th, 2025, we received another EB-1A (Alien of Extraordinary Ability) approval for a Research Assistant Professor in the Field of Genetic Epidemiology (Approval Notice).
General Field: Genetic Epidemiology
Position at the Time of Case Filing: Research Assistant Professor
Country of Origin: India
State of Residence at the Time of Filing: Michigan
Approval Notice Date: June 14th, 2025
Processing Time: 18 days (Premium Processing Requested)
Case Summary:
We are proud to share the approval of an I-140 petition under the EB-1A category for a genetic epidemiologist whose influential work has advanced the understanding of disease susceptibility and resistance mechanisms. This approval, secured in just under three weeks, affirms the petitioner’s extraordinary ability and the value of their contributions to global public health and biomedical research.
With a Ph.D. in zoology, the petitioner is recognized for their expertise in identifying causal genes and uncovering dysregulated pathways that drive disease risk. Among the most impactful areas of their research is the study of genetic polymorphisms in the vitamin D receptor (VDR) gene and its association with pulmonary tuberculosis (PTB), including drug-resistant strains. Their pioneering investigations have been foundational for further studies in infectious disease genomics and personalized medicine.
Currently working in academia, the petitioner applies advanced genetics and genomics techniques to understand the genetic architecture of musculoskeletal conditions such as rotator cuff tears and glenohumeral osteoarthritis. This research addresses critical challenges in orthopedic health and is shaping precision treatment strategies in this area.
To demonstrate the petitioner’s extraordinary ability, the I-140 petition emphasized:
● A strong publication record, including 14 peer-reviewed journal articles, 1 preprint, and 1 book chapter,
● A citation count of 219, evidencing significant use and recognition of their work by global peers,
● Over 40 instances of peer review service for top scientific journals and funding agencies, reflecting professional trust in their judgment,
● Ongoing research support from prominent funding bodies across multiple countries, highlighting the sustained international investment in their work.
The petitioner’s research has directly influenced other scientists worldwide, informing studies in genetic risk assessment, disease modeling, and public health interventions. Their publication venues include some of the highest-ranking journals in epidemiology, virology, and musculoskeletal medicine, underscoring the broad relevance and impact of their scholarship.
In addition, two expert letters of recommendation were submitted to USCIS, attesting to the major significance of the petitioner’s contributions. One letter stated:
“Considering the value presented by his tuberculosis (TB) genetic markers, risk prediction, and drug resistance detection tools, halting [Client’s] research would be damaging to disease prevention and public health systems. It is, therefore, within the interests of the US to allow [Client’s] research to continue.”
We congratulate this client on their EB-1A approval. Through NAILG, we are honored to support distinguished researchers like them whose exceptional expertise enhances the scientific and medical leadership of the United States.